CO5280204A1 - USE OF GLUTAMINE FOR THE PREVENTION OF LATE DIARRHEA INDUCED BY IRINOTECAN - Google Patents

USE OF GLUTAMINE FOR THE PREVENTION OF LATE DIARRHEA INDUCED BY IRINOTECAN

Info

Publication number
CO5280204A1
CO5280204A1 CO01002004A CO01002004A CO5280204A1 CO 5280204 A1 CO5280204 A1 CO 5280204A1 CO 01002004 A CO01002004 A CO 01002004A CO 01002004 A CO01002004 A CO 01002004A CO 5280204 A1 CO5280204 A1 CO 5280204A1
Authority
CO
Colombia
Prior art keywords
irinotecan
glutamine
prevention
diarrhea induced
late diarrhea
Prior art date
Application number
CO01002004A
Other languages
Spanish (es)
Inventor
Diane Savarese
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of CO5280204A1 publication Critical patent/CO5280204A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición que comprende una cantidad efectiva de glutamina para el uso en tratamiento de diarrea con inicio tardío inducida por irinotecan.A composition comprising an effective amount of glutamine for use in treatment of diarrhea with late onset induced by irinotecan.

CO01002004A 2000-01-18 2001-01-12 USE OF GLUTAMINE FOR THE PREVENTION OF LATE DIARRHEA INDUCED BY IRINOTECAN CO5280204A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48496200A 2000-01-18 2000-01-18

Publications (1)

Publication Number Publication Date
CO5280204A1 true CO5280204A1 (en) 2003-05-30

Family

ID=23926357

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01002004A CO5280204A1 (en) 2000-01-18 2001-01-12 USE OF GLUTAMINE FOR THE PREVENTION OF LATE DIARRHEA INDUCED BY IRINOTECAN

Country Status (4)

Country Link
AU (1) AU2001229478A1 (en)
CO (1) CO5280204A1 (en)
PE (1) PE20011042A1 (en)
WO (1) WO2001052828A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2295429A1 (en) * 2000-01-06 2001-07-06 Michael Michael Treatment or prevention of diarrhea
WO2004103371A1 (en) * 2003-05-21 2004-12-02 Pharmacia & Upjohn Company Llc Use of cftr inhibitors for the treatment of chemotherapy-induced diarrhea

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds

Also Published As

Publication number Publication date
WO2001052828A3 (en) 2002-04-18
AU2001229478A1 (en) 2001-07-31
PE20011042A1 (en) 2001-09-26
WO2001052828A2 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
AR027968A1 (en) A COMPOSITION TO USE IN THE TREATMENT AND / OR PREVENTION OF SARAMPION AND THE USE OF SUCH COMPOSITION FOR A VEHICLE FOR THE TREATMENT OR PREVENTION OF SARAMPION
AR045179A1 (en) USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND OF CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER
AR028296A1 (en) SYNERGISTIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
ES2422556T3 (en) Viral hepatitis treatment
HN2001000146A (en) PIRAZOL DERIVATIVES
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
ES2196160T3 (en) USE OF A COMBINATION OF TENSIOACTIVE, CHELLING AGENTS AND ESSENTIAL OILS FOR EFFECTIVE DISINFECTION.
BR0316203A (en) Use of an antiallergic agent and a steroid to treat allergic rhinitis
CL2004001293A1 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES ANTIBACTERIAL COMPOUNDS LIKE FLORFENICOL, TIAMPHENICOL, CHLORAMPHENICOL IN COMBINATION WITH AT LEAST A SELECTED CARRIER OF TRIACETINE, DIMETHYLETAMIDE OR A MIXTURE OF THEM; AND ITS USE IN THE TREATMENT OF U
PA8513601A1 (en) PHARMACEUTICAL COMPOSITIONS OF GLUCOGENOPHOSPHORILASE INHIBITORS
BRPI0410857A (en) method for treating depression, use of gaboxadol, and pharmaceutical composition
RS50682B (en) A combination comprising combrestatin and anticancer agents
UY27203A1 (en) USEFUL BENCIMIDAZOLS IN THE TREATMENT OF SEXUAL DYSFUNCTION
BR0210101A (en) Antineoplastic Combinations
ES2184341T3 (en) A METHOD FOR THE PREVENTION AND TREATMENT OF Myocardium Dysfunction.
BRPI0414114A (en) defibrotide use, formulation, and, method for treating a mammal affected by a tumor
RS51534B (en) NEW ASSOCIATION OF AN If SINUSOIDAL CURRENT INHIBITOR AND A CALCIUM CHANNEL-BLOCKING AGENT, AND PHARMACEUTICAL INGREDIENTS CONTAINING SAID ASSOCIATION
UY26171A1 (en) PHARMACEUTICAL FORMULATION AND METHOD FOR THE TREATMENT OF LATE APPEARANCE DYSKINESIA
AR043327A1 (en) USE OF QUINURENINE 3- HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES
CO5280204A1 (en) USE OF GLUTAMINE FOR THE PREVENTION OF LATE DIARRHEA INDUCED BY IRINOTECAN
AR063460A1 (en) SOLID COMPOSITION FOR WATER TREATMENT
AR028359A1 (en) COMPOSITION FOR THE CONTROL OF ARTROPODES
BR0111785A (en) Compositions and methods for treating candidiasis
EE200300213A (en) Use of SARP-1 for the treatment and / or prevention of scleroderma
ES2196769T3 (en) TOPICAL USE OF LOPERAMIDE FOR THE TREATMENT OF MICROBIAL INFECTIONS.

Legal Events

Date Code Title Description
FA Application withdrawn